Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

por Menzies, A M, Wilmott, J S, Long, G V, Scolyer, R A
Publicado 2014

External validation of a prognostic model to predict survival of patients with sentinel node‐negative melanoma

por Ipenburg, N. A., Nieweg, O. E., Ahmed, T., van Doorn, R., Scolyer, R. A., Long, G. V., Thompson, J. F., Lo, S.
Publicado 2019

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

por Hu, W, Jin, L, Jiang, C C, Long, G V, Scolyer, R A, Wu, Q, Zhang, X D, Mei, Y, Wu, M
Publicado 2013

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma

por Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V
Publicado 2013

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

por Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V
Publicado 2014

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients

por Lee, J H, Saw, R P, Thompson, J F, Lo, S, Spillane, A J, Shannon, K F, Stretch, J R, Howle, J, Menzies, A M, Carlino, M S, Kefford, R F, Long, G V, Scolyer, R A, Rizos, H
Publicado 2019

A distinct molecular profile associated with mucinous epithelial ovarian cancer

por Heinzelmann-Schwarz, V A, Gardiner-Garden, M, Henshall, S M, Scurry, J P, Scolyer, R A, Smith, A N, Bali, A, Bergh, P Vanden, Baron-Hay, S, Scott, C, Fink, D, Hacker, N F, Sutherland, R L, O'Brien, P M
Publicado 2006

Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections

por Schmitt, C., Hoefsmit, E. P., Fangmeier, T., Kramer, N., Kabakci, C., Vera González, J., Versluis, J. M., Compter, A., Harrer, T., Mijočević, H., Schubert, S., Hundsberger, T., Menzies, A. M., Scolyer, R. A., Long, G. V., French, L. E., Blank, C. U., Heinzerling, L. M.
Publicado 2023

Mucosal‐associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy‐related colitis in a patholog...

por Sasson, S. C., Zaunders, J. J., Nahar, K., Munier, C. M. L., Fairfax, B. P., Olsson‐Brown, A., Jolly, C., Read, S. A., Ahlenstiel, G., Palendira, U., Scolyer, R. A., Carlino, M. S., Payne, M. J., Cheung, V. T. F., Gupta, T., Klenerman, P., Long, G. V., Brain, O., Menzies, A. M., Kelleher, A. D.
Publicado 2020

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

por O'Brien, P M, Davies, M J, Scurry, J P, Smith, A N, Barton, C A, Henderson, M J, Saunders, D N, Gloss, B S, Patterson, K I, Clancy, J L, Heinzelmann-Schwarz, V A, Scolyer, R A, Zeng, Y, Williams, E D, Scurr, L, DeFazio, A, Quinn, D I, Watts, C K W, Hacker, N F, Henshall, S M, Sutherland, R L
Publicado 2008

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro

por O'Brien, P M, Davies, M J, Scurry, J P, Smith, A N, Barton, C A, Henderson, M J, Saunders, D N, Gloss, B S, Patterson, K I, Clancy, J L, Heinzelmann-Schwarz, V A, Murali, R, Scolyer, R A, Zeng, Y, Williams, E D, Scurr, L, DeFazio, A, Quinn, Di, Watts, C K W, Hacker, N F, Henshall, S M, Sutherland, R L
Publicado 2008